This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
CLN-0046
A Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD).
This trial is undertaken by the Centre for Eye Research Australia.
Overview
This study aims to assess a new implant called OTX–TKI, which contains the study drug axitinib.
The purpose of this study is to evaluate how safe, tolerable and effective the OTX–TKI is in treating wet age-related macular degeneration (AMD) with two different doses of axitinib.
The OTX-TKI implant is injected into the vitreous of the eye (the jelly-like substance that fills the eyeball), and monitored until the implants slowly break down and are eventually cleared from the eye.
Regular visits are scheduled for a minimum of 9 months from the implant date.
- Principal Investigator
Associate Professor Sanj Wickremasinghe
This study aims to assess a new implant called OTX–TKI, which contains the study drug axitinib.
The purpose of this study is to evaluate how safe, tolerable and effective the OTX–TKI is in treating wet age-related macular degeneration (AMD) with two different doses of axitinib.
The OTX-TKI implant is injected into the vitreous of the eye (the jelly-like substance that fills the eyeball), and monitored until the implants slowly break down and are eventually cleared from the eye.
Regular visits are scheduled for a minimum of 9 months from the implant date.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This international database listing provides more detailed information about this study.